SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Surrozen, Inc./DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.84+0.40 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $551.80M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$10.26 (+75.55%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Surrozen, Inc./DE saw revenue fall 8.8% to $11.51M over the twelve months to Jun 30, 2026. Free cash flow was -$34.98M.
Revenue
$11.51M
-8.8% vs. a year earlier
Operating income
-$44.35M
TTM Q2 2026
Free cash flow
-$34.98M
TTM Q2 2026
EPS, diluted
-$32.37
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $551.80M
- P/E ratio
- –
- Price to sales
- 47.94
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6.34%
Fundamentals
- Revenue
- $11.51M
- Net income
- -$332.13M
- EPS, diluted
- -$32.37
- Free cash flow
- -$34.98M
- Book value per share
- -$9.45
- Diluted shares
- 23M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$11.51M-8.8% YoY
Operating income
-$44.35M
Net income
-$332.13M
EPS, diluted
–
Free cash flow
-$34.98M
Reported periodTrailing twelve months